Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.18 USD | +3.58% | +4.26% | -18.04% |
Apr. 18 | Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board | CI |
Mar. 12 | Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024 | CI |
Business Summary
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Amit Kumar
CEO | Chief Executive Officer | 59 | 12-10-31 |
Michael Catelani
DFI | Director of Finance/CFO | 57 | 16-10-31 |
Pamela Garzone
PRN | Corporate Officer/Principal | 69 | 21-09-06 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Lewis Titterton
BRD | Director/Board Member | 79 | 99-06-30 |
Amit Kumar
CEO | Chief Executive Officer | 59 | 12-10-31 |
Emily Gottschalk
BRD | Director/Board Member | 63 | 19-10-22 |
Arnold Baskies
BRD | Director/Board Member | 74 | 16-07-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 31,899,800 | 30,335,901 ( 95.10 %) | 0 | 95.10 % |
Company contact information
Anixa Biosciences, Inc.
3150 Almaden Expressway Suite 250
95118, San Jose
+408 708 9808
http://www.anixa.comSector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.04% | 97.93M | |
+4.09% | 43.43B | |
+47.81% | 41.69B | |
+9.45% | 41.31B | |
-10.92% | 27.14B | |
+9.32% | 25.28B | |
-24.87% | 18.47B | |
+29.70% | 12.59B | |
+1.28% | 12.33B | |
+7.78% | 11.03B |
- Stock Market
- Equities
- ANIX Stock
- Company Anixa Biosciences, Inc.